Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma.

A total of 134 901 patients with conservatively managed nontraumatic subdural hematoma were identified, of whom 1470 (1.1%) were GLP-1 RA users.

After propensity score matching, 2922 patients remained, with 1461 in each group.

All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards.

GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05).